Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
Hong Kong · Delayed Price · Currency is HKD 7.10
-0.01 (-0.14%)
At close: Apr 17, 2026
HKG:2566 Revenue
In the year 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical had annual revenue of 1.31B CNY, down -4.59%. Hangzhou Jiuyuan Genetic Biopharmaceutical had revenue of 667.52M in the half year ending December 31, 2025, with 6.98% growth.
Revenue
1.31B CNY
Revenue Growth
-4.59%
P/S Ratio
1.18
Revenue / Employee
728.15K CNY
Employees
1,794
Market Cap
1.72B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | -62.88M | -4.59% |
| Dec 31, 2024 | 1.37B | 81.78M | 6.35% |
| Dec 31, 2023 | 1.29B | 162.00M | 14.40% |
| Dec 31, 2022 | 1.13B | -181.85M | -13.91% |
| Dec 31, 2021 | 1.31B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| Mabpharm | 718.98M |
| Cutia Therapeutics | 374.07M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| CANbridge Pharmaceuticals | 55.62M |
| Kintor Pharmaceutical | 36.37M |
| Zhaoke Ophthalmology | 35.58M |
| Transcenta Holding | 8.27M |